Axsome Therapeutics(NASDAQ) AXSM

Axsome Therapeutics makes medicines for brain and nervous system conditions. Its treatments help adults manage depression, migraines, and sleep disorders. The company focuses on creating new ways to improve mental health.

Mental Health and Sleep Treatments

• AUVELITY: Oral treatment for adults with major depressive disorder (MDD) or agitation related to Alzheimer’s disease.
• SUNOSI: Tablet taken for excessive daytime sleepiness (EDS) caused by narcolepsy or obstructive sleep apnea.
• SYMBRAVO: Rapidly absorbed oral medicine used for the acute treatment of migraine attacks in adults.
• Pipeline Candidates: Experimental drugs in development for conditions including fibromyalgia, epilepsy, narcolepsy, and schizophrenia.

Strategic Steps and Drug Buys

• Acquired the United States and international rights to SUNOSI from Jazz Pharmaceuticals in 2022.
• Licensed European and Middle Eastern marketing rights for SUNOSI to Pharmanovia in February 2023.
• Secured a senior secured term loan agreement for up to $570 million with Blackstone in May 2025.
• Acquired global rights to balipodect (AXS-20) from Takeda Pharmaceutical Company for $10.4 million in early 2026.
• Launched AUVELITY for the treatment of agitation associated with dementia due to Alzheimer’s disease in June 2026.

Solving Complex Brain Conditions

Axsome uses proprietary metabolic inhibition technology to control how the body processes and delivers its medicinal components. This operational approach allows the company to develop treatments with unique doses and rapid-acting efficacy for psychiatric and neurological conditions.

Revenue Growth and Research Costs

• Total revenues reached $218.4 million for the three months ended June 30, 2026, compared to $150.0 million in 2025.
• Net loss was $115.9 million for the six months ended June 30, 2026, compared to $107.4 million in 2025.
• U.S. net sales of AUVELITY were $333.0 million for the six-month period ended June 30, 2026.
• Accumulated deficit was $1.42 billion as of June 30, 2026, due to ongoing commercialization and research costs.

Building a Commercial Powerhouse

Axsome has transitioned from a research firm into a commercial producer of central nervous system treatments. Expanding its approved uses and acquiring new drug candidates supports its long-term move toward profitability.